Status:
TERMINATED
A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Neoplasms
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
The clinical study will evaluate safety, tolerability and Pharmacokinetics of MK0683 in combination with carboplatin and paclitaxel in chemotherapy-naive NSCLC patients.
Eligibility Criteria
Inclusion
- Chemotherapy-naive patients who are histologically or cytologically diagnosed NSCLC with stage IIIB (not applicable of radical thoracic radiation) or stage IV
- Patients with normal organ function and bone marrow function
Exclusion
- Given radical thoracic radiation for NSCLC or radiation for other than original lesion within 3 weeks
- Any peripheral neuropathy above grade 2
- Any ascites, pleural effusion or pericardiac effusion which requires treatment
- Any uncontrolled concomitant illness
- Pregnant or breast-feeding
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2007
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT00424775
Start Date
January 1 2007
End Date
March 1 2007
Last Update
April 20 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.